Evity 8 HF-T QP Offers a Host of Functions Including LV VectorOpt, RF Telemetry, MRI AutoDetect and BIOTRONIK Home Monitoring
TOKYO, Japan and BERLIN, Germany, July 10, 2017 – BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese market. It is the company’s highest performing CRT-P with a battery life of almost 10 years.
Quadripolar technology allows for increased options in pacing the left ventricle (LV). The device comes with a new feature, LV VectorOpt, which allows for easy testing and selection of the optimal pacing vector, while SafeSync RF Telemetry establishes a wireless connection between implant and programmer during implantation and follow-up.
The new CRT-P is approved for full-body, 1.5 tesla (T) MRI scans. It also features BIOTRONIK’s award-winning MRI AutoDetect, a built-in sensor that detects an MRI environment and automatically switches the device to MRI mode, returning to normal settings after the scan.
Dr. Yuji Nakazato, Juntendo University Urayasu Hospital, Tokyo, Japan, commented, “When choosing a CRT-P device we always consider three points. We check if the device has quadripolar pacing, is MRI conditional and has acceptable longevity. The Evity CRT-P meets all these criteria with 13 LV pacing vectors, 1.5 T full-body MRI capability, and an exceptional battery life. Thus we expect this device to be good not only for patients, but our physicians and staff as well.”
Evity also features BIOTRONIK Home Monitoring®, which streamlines workflow and has been demonstrated to reduce hospitalization for atrial arrhythmias and related stroke in pacemaker patients.1 Home Monitoring automatically collects cardiovascular data from the patient’s device and transmits it remotely to the physician without any need for patient interaction.
“We strive to give physicians the best treatment options based on patients’ individual needs,” said Jeffrey Annis, Managing Director, BIOTRONIK Japan. “The Evity quadripolar CRT-P device offers highly innovative pacing technology for improved patient outcomes, as well as the cache of BIOTRONIK specifications that physicians in Japan have come to trust.”
About BIOTRONIK
A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar, the world’s first 4 F compatible stent for treating long lesions; Orsiro, the industry’s first hybrid drug-eluting stent; and the world’s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.
